The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
Open accessAbstract
Aims/hypothesis The aim of this study was to evaluate the risk of adverse cardiovascular outcomes in patients with type 2 diabetes newly treated with sulfonylureas and metformin.Subjects and methods The Diabetes Audit and Research in Tayside Scotland (DARTS) diabetes information system and the Medicines Monitoring Unit (MEMO) dispensed prescribing database for the population of Tayside, Scotland (400,000 people) were employed. Patients newly prescribed with oral hypoglycaemic agents between 1994 and 2001 were classified into five study cohorts according to the treatment received: metformin only, sulfonylureas only, sulfonylureas added to metformin, metformin added to sulfonylureas, and both drugs simultaneously. In Cox regression analyses, we estimated relative risks for all-cause mortality, cardiovascular mortality and cardiovascular hospital admission for patients in the five study cohorts, with metformin monotherapy as the reference group.Results Of the 5,730 study patients, 1,000 died during a maximum of 8 years follow-up. Patients in the sulfonylureas only cohort had increased risks of mortality and cardiovascular mortality, with unadjusted relative risks of 3.12 (95% CI 2.54-3.84) and 3.71 (95% CI 2.64-5.22), respectively. After adjusting for differences between groups (age, sex, duration of diabetes, blood pressure, cholesterol, HbA(1c), smoking, previous hospital admission, treatment with cardiovascular medication), these relative risks were 1.43 (95% CI 1.15-1.77) and 1.70 (95% CI 1.18-2.45), respectively. Patients in the combination cohorts had significantly increased risks of cardiovascular hospital admission, as well as increased risks of mortality and cardiovascular mortality.Conclusions/interpretation In this cohort study of patients newly treated with oral hypoglycaemic agents, those treated with sulfonylureas only, or combinations of sulfonylureas and metformin, were at higher risk of adverse cardiovascular outcomes than those treated with metformin alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiological investigations suggest that patients on SUs have a higher cardiovascular disease event rate than those on metformin.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [27]
In the citing paper
“Patients who started SUs first and added metformin also had higher rates of cardiovascular disease events compared with those who started metformin first and added SUs.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
International statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Deprivation and Health in Scotland
Tunstall-Pedoe, H. (1993) · Postgraduate Medical Journal · doi:10.1136/pgmj.69.814.665-a · Cited by 1,171
Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death.
Schneider, B. A. (1953) · The Quarterly Review of Biology · doi:10.1086/399926 · Cited by 1,000
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Morris, A. D., Boyle, D. I., MacAlpine, R., Emslie-Smith, A. M., Jung, R. T., Newton, R. W., & MacDonald, T. M. (1997) · BMJ · doi:10.1136/bmj.315.7107.524 · Cited by 297
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–293 of 293
Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2
Kusturica, J., Kulo, A., Gušić, E., Kapo, S. M., Rakanović-Todić, M., & Šečić, D. (2017) · Medicinski Glasnik · doi:10.17392/910-17 · Cited by 7
Metformina y diabetes mellitus tipo 2
Mata‐Cases, M. (2008) · Atención Primaria · doi:10.1157/13116631 · Cited by 7
Metformin and other biguanides: pharmacology and therapeutic usage
Samson, S. L., & Garber, A. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch43 · Cited by 7
Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN
Prieto-Díaz, M. Á., Samper, J. M. C., Cervantes, C. E., & Molinera, V. G. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.04.005 · Cited by 6
Kim, Y. S., Cho, B., Kim, W. S., Kim, S., Jung, I. H., Sin, W.-Y., Choi, D., Lee, S. J., Lim, C. S., Kang, K. P., et al. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.18.0051 · Cited by 6
Adverse Events Due to Oral Hypoglycemic Drugs
Nanditha, A., & Vettath, R. E. (2024) · Springer eBooks · doi:10.1007/978-981-97-6406-8_21 · Cited by 7
Bohannon, N. J. V. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2572 · Cited by 6
Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes
Guthrie, R. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1430446 · Cited by 6
Metformin – from Devil to Angel
Schernthaner, G., & Schernthaner, G.-H. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_9 · Cited by 6
Raccah, D. (2007) · Diabetologia · doi:10.1007/s00125-007-0630-3 · Cited by 6
Kautzky‐Willer, A., & Lemmens‐Gruber, R. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_15 · Cited by 6
Optimal Glycemic Control in the Elderly: Where is the Evidence and Who Should Be Targeted?
Tessier, D. (2011) · Aging Health · doi:10.2217/ahe.10.86 · Cited by 5
Biondi‐Zoccai, G., Pinto, A., Versaci, F., Procaccini, E., Neri, G., Sesti, G., Uccioli, L., Vetere, M., Peruzzi, M., & Nudi, F. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000399 · Cited by 5
EDMONDS, M. E. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-22 · Cited by 5
Adeneye, A. A., & Olagunju, J. A. (2012) · Pharmacologia · doi:10.5567/pharmacologia.2012.665.671 · Cited by 5
Sulfonylureas and meglitinides: insights into physiology and translational clinical utility
Lebovitz, H. E., & Melander, A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch42 · Cited by 5
Chun, K., Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J., Lee, H., Hwang, K., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101504 · Cited by 5
Bloomer, K. (2019) · British Paramedic Journal · doi:10.29045/14784726.2019.09.4.2.10 · Cited by 4
Bakhteyari, A., Nikpour, P., Mostafavi, F. S., Eskandari, N., Matinfar, M., Asl, S. S., & Aboutorabi, R. (2019) · Europe PMC (PubMed Central) · doi:10.22074/ijfs.2019.5636 · Cited by 4
Metformin Associated Lactic Acidosis in Clinical Practice – A Case Series
Schädle, P., Tschritter, O., & Kellerer, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1149-9030 · Cited by 4
Vascular disease in paediatric type 2 diabetes: the state of the art
Vaughan, T. B., Ovalle, F., & Moreland, E. C. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.056 · Cited by 4
Bailey, C. J. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_8 · Cited by 4
Evans, J. M. M., & Morris, A. D. (2007) · Diabetologia · doi:10.1007/s00125-007-0632-1 · Cited by 4
Self-citationWhat's the latest on sulphonylureas in the management of type 2 diabetes?
Mkele, G. (2013) · South African Family Practice · doi:10.1080/20786204.2013.10874405 · Cited by 4
Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes
Guthrie, R. M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174566 · Cited by 3
Translational Endocrinology & Metabolism: Metabolic Surgery Update
DEL PRATO, S., & Lebovitz, H. E. (2012) · Translational endocrinology & metabolism · doi:10.1210/team.9781936704071 · Cited by 3
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-3 · Cited by 3
Tratamiento de la diabetes tipo 2: revisión de las opciones y prioridades terapéuticas actuales
Arroyo, J., Caixàs, A., & Pi‐Sunyer, F. X. (2007) · Medicina Clínica · doi:10.1157/13113289 · Cited by 3
Suthar, S. D., Dholaria, N. K., Chavda, D. A., Chacko, J., Bhansali, N. B., Gosai, T. R., & Trivedi, H. R. (2014) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-014-0224-9 · Cited by 3
Miranda, V. P., Rodrigues, M., Rocha‐Gonçalves, F., & Nunes, J. P. L. (2009) · PubMed · Cited by 3
Chang, Y., Choi, N., Hahn, S., & Park, B. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1465 · Cited by 3
Yao, Q., Liu, H., Wang, X., Zhang, Z., Xie, H., Xie, C., & Gao, H. (2026) · Biological Research · doi:10.1186/s40659-025-00665-8 · Cited by 5
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy
Kanki, M., & Young, M. J. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.01.004 · Cited by 3
Metformin-Associated Lactic Acidosis in an Older Adult: A Case Report and Review
Jain, S., Sekhon, S., Chandran, A. S. L. P., Gummadi, J., Patel, P., Nakka, R., Gunendran, T., Nanjundappa, A., Jose, T., Garapati, H. N., et al. (2024) · Cureus · doi:10.7759/cureus.62729 · Cited by 2
Tratamiento combinado de la diabetes mellitus tipo 2
Mata‐Cases, M. (2008) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(08)70768-0 · Cited by 2
Risk Reduction in the Diabetic Patient
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8_14 · Cited by 2
Khalangot, M. D., Gurianov, V. G., Kovtun, V. A., Okhrimenko, N., Kravchenko, V. I., & Tronko, M. D. (2011) · InTech eBooks · doi:10.5772/20607 · Cited by 2
Mazón‐Ramos, P., Cordero, A., González‐Juanatey, J. R., Bertoméu, V., Delgado, E., Vitale, G. C., & Fernández-Anaya, S. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.03.021 · Cited by 2
Where do sulphonylureas fit in the type 2 diabetes guidelines?
Mkele, G. (2014) · South African Family Practice · doi:10.4102/safp.v56i4.4190 · Cited by 2
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Metzendorf, M., Richter, B., & Hemmingsen, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368 · Cited by 3
Pachiappan, S., Sukumaran, A., Mathew, S. R., Varghese, S., & Aloysious, T. (2018) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2018.8305 · Cited by 2
Nishimura, R., Takeshima, T., Iwasaki, K., & Aoi, S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206016 · Cited by 3
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 2
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Bell, D. S. H. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0233 · Cited by 2
The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
Petunina, N. A., Martirosian, N. S., Валерьевна, Г. Е., Эдуардовна, Т. М., Кузина, И. А., Олеговна, Щ. А., & Акрамовна, Э. Э. (2024) · Diabetes Mellitus · doi:10.14341/dm13184 · Cited by 1
Antidiabéticos orales y riesgo cardiovascular
Sansone, S., & del Pilar, M. (2012) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 1
Hua, S., Hwang, J., & Chang, Y. (2015) · Journal of Cardiology and Therapy · doi:10.17554/j.issn.2309-6861.2015.02.87 · Cited by 1
Strongman, H., D’Oca, K., Langerman, H., & Das, R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12458 · Cited by 1
Ahluwalia, R., & Vora, J. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651411431846 · Cited by 1
Kardiovaskuläre Effekte von Metformin, Sulfonylharnstoffen und Gliniden
Forst, T. M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0082-9 · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Akyay, Ö. Z., Sahin, T., Çakmak, Y., Tarkun, İ., Selek, A., Cantürk, Z., Çetinarslan, B., & Karakaya, D. (2022) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_1640_21 · Cited by 2
Management of Patients with Chronic Heart Failure and Diabetes Mellitus
Reznik, E. V., Nguyen, T. L., & Golukhov, G. N. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-04-05 · Cited by 1
Renal Dysfunction and Hypertension
Mogensen, C. E. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-20 · Cited by 1
Linking existing databases to monitor and improve diabetes care
Joshy, G. (2010) · ResearchSpace (University of Auckland) · Cited by 1
Chun, K., Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J.-O., Lee, H., Hwang, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3103721/v1 · Cited by 1
Metabolic Regulation of Endothelial Dysfunction and Cardiovascular Risk
Young, J. M. (2012) · Otago University Research Archive (University of Otago)
CLINICAL ASPECTS ON GLUCOSE-LOWERING THERAPIES IN TYPE 2 DIABETES
Nybäck‐Nakell, Å. (2012) · Figshare
Time to be cautious about prescribing sulfonylureas?
Dwyer, M. (2015) · British Journal of General Practice · doi:10.3399/bjgp15x683617
Blake, E., & Sease, J. M. (2009) · Journal of Pharmacy Technology · doi:10.1177/875512250902500105
The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease
Cheng, J. W. M., Bhatt, S. H., & Goldman, J. D. (2008) · Journal of Pharmacy Practice · doi:10.1177/0897190008326104
Veneman, T. F. (2014) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-014-0016-3
3. Glycemic Management of Type 2 Diabetes
D’Alessio, D. A., & Hirsch, I. B. (2011) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225824.ch3
Prieto-Díaz, M. Á., Escobar, C., & Molinera, V. G. (2014)
Auf der Suche nach dem idealen Antidiabetikum
Reisdorf, S. (2014) · Info Diabetologie · doi:10.1007/s15034-014-0700-9
Gosmanova, E. O., Canada, R. B., Wan, J. Y., Mangold, T. A., & Wall, B. M. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182621dbf · Cited by 1
Update of the evidence-based guideline of the German Diabetes Association
Matthaei, S., Bierwirth, R., Fritsche, A., Häring, U., Kellerer, M., Kunt, T., Schernthaner, G., Siegel, E. G., & Thienel, F. (2008)
Metformin revisited : an ‘old’ drug with a ‘new’ beginning
Vella, S. (2013) · OAR@UM (University of Malta)
Halimi, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30052-4
ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS
Kabade, D. M., Koppad, A., Khatawkar, A. V., Kabade, S. D., & Ahmed, A. (2016) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2016/503
Fall 66: Therapie – 57 Jahre, ♂, DM Typ 2, koronare Herzerkrankung
Sulaj, A. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_66
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-1
Полторак, В. В., Кравчун, Н. А., Горшунская, М. Ю., & Krasova, N. S. (2014) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.1.57.2014.76425
Al-Ezzy, R. M. (2019) · American Journal of Bioscience and Bioengineering · doi:10.11648/j.bio.20190701.12
Kim, E. H., Kim, S. S., Kim, D. J., Choi, Y. S., Lee, C. W., Ku, B. J., Cha, K. S., Song, K. H., Kim, D.-K., & Kim, I. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-75594-5
Tkachenko, V. I., & Sadovnik, I. (2016) · Medicine of Ukraine · doi:10.37987/1997-9894.2016.3(199).203681
Dubois, T. B. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3gt5fx4s
The modifying effects of adiposity on the cardiovascular safety of sulphonylureas
Suissa, K., Schneeweiß, S., Douros, A., Filion, K. B., Yin, H., Patorno, E., & Azoulay, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14494
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282c3a898
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280d5f7e9
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_6
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_6
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-2
Current literature in diabetes
(2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.720
Macías-Batista, A., Martínez, I. P., & de Pablos-Velasco, P. L. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76264-8
Jamieson, A. (2022) · doi:10.1093/med/9780198766223.003.0035
Pho, N. V., & Hương, N. T. T. (2022) · TẠP CHÍ KHOA HỌC TRƯỜNG ĐẠI HỌC QUỐC TẾ HỒNG BÀNG · doi:10.59294/hiujs.vol..2022.388
Andrew Gnanaprakasam, J., Veeramani, G., & MANJANNA, K. (2023) · International Journal of Membrane Science and Technology · doi:10.15379/ijmst.v10i2.2817
Delbaere, J., Deboever, E., Vaes, B., Nobels, F. R. E., Mamouris, P., & Goderis, G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.003 · Cited by 1
Diabetes &endocrinology: something for everyone
Pearson, E. R. (2009) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520093901020
Lawrence, W. (2020) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/76w3-wfa9
The effects of metformin on metabolism and cardiovascular disease in type 2 diabetes
de Jager, J. (2010) · Research Publications (Maastricht University) · doi:10.26481/dis.20100527jj
Metadata
- Authors
- Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D.
- Affiliations
- University of Dundee (GB)
- The Mill (GB)
- Corresponding author
- Evans, J. M. M.
- Venue
- Diabetologia
- Published
- 2006-03-09
- Volume
- 49
- Issue
- 5
- Pages
- 930-936
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2114349038
- Cited by
- 293
- References
- 19
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 13 · 2018: 15 · 2017: 11 · 2016: 21 · 2015: 13 · 2014: 23 · 2013: 28 · 2012: 24
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Stirling Online Research Repository (University of Stirling) (submittedVersion, public-domain)
- Funders
- Diabetes UK
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, sulfonylureas, metformin, oral antidiabetic drugs, cardiovascular mortality, all-cause mortality, cardiovascular hospital admissions, cardiovascular adverse events, combination therapy, newly treated patients
- MeSH terms
- Adult, Aged, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Female, Hospitalization, Humans, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, Scotland, Sulfonylurea Compounds, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
